Suggestions
Danielle Carnival
CEO at I AM ALS
Danielle Carnival, PhD, is a prominent American neuroscientist and healthcare leader, currently serving as the Deputy Assistant to the President for the Cancer Moonshot and Deputy Director for Health Outcomes in the White House Office of Science and Technology Policy. She plays a key role in advancing initiatives aimed at improving health outcomes and reducing cancer mortality rates in the United States.
Education and Early Career
Dr. Carnival earned her Bachelor of Science in Biochemistry from Boston College in 2005 and completed her Ph.D. in Neuroscience at Georgetown University in 2010. Her doctoral dissertation focused on the regulation of AMPA receptor strength by Polo-like kinase 2, under the supervision of Daniel Pak.12
Professional Background
Before her current roles, Dr. Carnival was the CEO of I AM ALS, a nonprofit organization dedicated to raising awareness and resources for amyotrophic lateral sclerosis (ALS), from 2019 to 2021. During her tenure, she led efforts to reshape public understanding of ALS and empower patients.13 Prior to that, she served as Vice President of the Biden Cancer Initiative, where she was instrumental in developing strategies to accelerate progress in cancer research and care.24
Dr. Carnival's experience also includes over six years at the White House, where she held various leadership positions related to health and biomedical policy. She was notably involved in initiatives such as the White House Cancer Moonshot, which aims to end cancer as we know it, and has contributed to numerous programs focused on STEM education and diversity.134
Current Role
In her current capacity since February 2023, Dr. Carnival leads efforts under the Biden-Harris administration to coordinate actions that prevent, detect, and treat cancer while enhancing support for families affected by the disease.34 Her work emphasizes collaboration with private organizations and governmental agencies to achieve significant health outcomes.
Dr. Carnival's leadership is characterized by a commitment to integrating scientific expertise with public health initiatives, making her a key figure in shaping health policy in the United States.
Highlights



